Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of days from treatment initiation to resolution of symptoms or signs (shorter is favored) · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
It is very uncertain whether PCC changes mortality (30‐day) compared with FVIIa (very low certainty).
1 finding from 1 review
Mortality (30‐day) · cardiac surgery for the treatment of non‐surgical bleeding
PCC showed no clear difference in mortality (30‐day) compared with standard treatment (moderate certainty).
1 finding from 1 review
Intervention not reported
Deep surgical site infection at 30 days or 90 days, or time points reported by study authors · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for mechanical invasive ventilation – up to and including 30 days · people with AHF
1 finding from 1 review
% Change in serum creatinine – at 30 days from discharge · people with AHF
1 finding from 1 review
Duration of antifungal use (days) · people with cancer who have febrile neutropenia
It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).
1 finding from 1 review
Number of exacerbations(as reported by number of hospitalisations and number of courses and days on antibiotics) · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes number of exacerbations(as reported by number of hospitalisations… compared with placebo (very low certainty).
1 finding from 1 review
Death or stroke · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in 30‐day post‐randomisation death/stroke compared with medical treatment alone (low certainty).
1 finding from 1 review
Fatal/non‐fatal stroke in the territory of the treated vertebral artery stenosis(assessed after 30 days post‐randomisation to completion of · people with vertebral artery stenosis
Endovascular treat ment plus medical treatment showed no clear difference in fatal/non‐fatal stroke in the territory of the treated vertebral… compared with medical treatment alone (moderate certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality by day 60 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab showed no clear difference in all‐cause mortality by day 60 compared with placebo (low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Development of clinical COVID‐19 symptoms within 30 days · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab leads to lower development of clinical COVID‐19 symptoms within 30 days compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review